Navigation Links
Quark Announces Dosing of the First Patient in Phase I Clinical Trial of its Ocular Neuroprotective Agent, QPI-1007
Date:3/1/2010

Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "Based on the pre-clinical results we've seen for QPI-1007, we are pleased to initiate dosing in human clinical trials. QPI-1007 is a siRNA molecule with Quark's proprietary structure and its entry into clinical trials reflects the Company's success in developing novel siRNA compounds.  These accomplishments further validate Quark's ability to advance innovative product candidates from discovery into the clinic."

Dr. Daniel Zurr, Quark's Chief Executive Officer, said, "The initiation of dosing in this trial brings the total number of siRNA programs in the clinic to five, an unprecedented number in the RNAi industry.  Beyond the size of our clinical stage siRNA portfolio, we are proud that this particular product, QPI-1007, was developed using entirely independent structural IP, further demonstrating our leadership in the field."

QPI-1007 is Quark's first siRNA drug candidate to utilize intellectual property developed internally in collaboration with BioSpring GmbH, and gives Quark freedom to operate in the siRNA IP space.  Preclinical studies have demonstrated a robust neuroprotective effect of QPI-1007 when administered immediately after injury induced by optic nerve crush or axotomy in two models of retinal ganglion cell (RGC) death as well as in a rat intraocular pressure (IOP) elevation model in which the dru
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
2. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
3. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
4. Quark Pharmaceuticals Presents at Asia TIDES Conference
5. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
6. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
7. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... LifeVantage Corporation (OTCBB: LFVN), makers of ... that Douglas C. Robinson, the Company,s President and Chief ... Science Officer, will be presenting at the Rodman & ... September 11-13, 2011, at the Waldorf Astoria in New ...
... TALLAHASSEE, Fla., Aug. 31, 2011 A recent study ... dispels the myth that physicians, offices use prostate ... The article, "Utilization Trends in Prostate ... utilization of both surgical and radiation therapy for management ...
Cached Medicine Technology:LifeVantage to Present at Rodman & Renshaw Annual Global Investment Conference 2Study Explores Utilization Trends for Prostate Cancer Treatments 2
(Date:12/26/2014)... Texas (PRWEB) December 26, 2014 Yisrayl Hawkins, ... written an open letter in light of the Ferguson, Missouri ... history of civil unrest and explains why it has only ... reason mankind was even created. He says there is a ... detail. Yisrayl also says there is a set of rules, ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the ... for 2014. The awards program, created in 2000, is ... in the country. The program is a public/private partnership ... and Economic Development, the Pennsylvania State Council of the ... Business Journal. , Charlie Wilson, Vice President ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... imaging (MRI) shows that childhood stress such as ... with genetic factors, can result in structural brain ... depression. The study led by scientists at Trinity ... international scientific journal, Neuropsychopharmacology . Commenting on ...
... chemotherapy followed by radiation to preserve their larynx have ... experienced no eating or swallowing problems, according to a ... Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ... is the current standard treatment for patients with cancer ...
... maximal standardized uptake value (called SUVmax) measured from ... in head and neck squamous cell carcinoma patients ... survival, overall survival and disease-free survival, while pretreatment ... metastasis, according to a study presented at the ...
... than Canada, study finds , THURSDAY, Feb. 25 (HealthDay ... among women, explain why arthritis is more common in ... new study. , Researchers at the Toronto Western Research ... that the prevalence of arthritis in the United States ...
... WellNet ... performance management strategies are the way to more effectively control healthcare costs across the ... Bethesda, ... Healthcare Performance Management (HPM) Institute, WellNet today expressed its support for -- and agreement ...
... TeraMedica ... its revolutionary Evercore® – Enterprise Clinical Suite software system, now available on Red Hat ... ... a leading medical informatics company, has launched a new enterprise platform for its revolutionary ...
Cached Medicine News:Health News:Childhood stress such as abuse or emotional neglect can result in structural brain changes 2Health News:Pretreatment SUV associated with head and neck cancer treatment outcomes, may help decide treatment plans 2Health News:WellNet Supports HPM Institute Director in Calling for More Active Enterprise Involvement in Managing Healthcare Quality and Costs 2Health News:TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux 2
The VISERA Multi-Specialty Digital Imaging Platform is the world's first integrated system of digital rigid, deflectable tip and flexible videoscopes for use in operating room endosurgery as well as ...
... and carbon dioxide, originally developed for neonatal ... of different applications, including vascular and wound ... surgery. TcpO2 measurements usually require at least ... good picture. The more sites that are ...
For continuous intracranial monitoring of pressure, oxygen and temperature of the brain...
Cutting Burr with dental shank, tungsten carbide, 0,7 mm, ISO-No. 007, packing unit 10 pieces....
Medicine Products: